Abstract:Background: N-glycolylneuraminic acid (Neu5Gc) is a non-human red-meat-derived sialic acid immunogenic to humans. Neu5Gc can be metabolically incorporated into glycan chains on human endothelial and epithelial surfaces. This represents the first example of a "xeno-autoantigen", against which circulating human "xeno-autoantibodies" can react. The resulting inflammation ("xenosialitis") has been demonstrated in human-like Neu5Gc-deficient mice and contributed to carcinoma progression via antibody-mediated inflammation. Anti-Neu5Gc antibodies have potential as biomarkers for diseases associated with red meat consumption such as carcinomas, atherosclerosis, and type 2 diabetes. Methods: ELISA assays measured antibodies against Neu5Gc or Neu5Gc-glycans in plasma or serum samples from the Nurses' Health Studies, the Health Professionals Follow-up Study, and the European Prospective Investigation into Cancer and Nutrition, including inter-assay reproducibility, stability with delayed sample processing, and within-person reproducibility over 1-3 years in archived samples. We also assessed associations between antibody levels and coronary artery disease risk (CAD) or red meat intake. A glycan microarray was used to detected antibodies against multiple Neu5Gc-glycan epitopes. A nested case-control study design assessed the association between total anti-Neu5Gc antibodies detected in the glycan array assay and the risk of colorectal cancer (CRC). Results: ELISA assays showed a wide range of anti-Neu5Gc responses and good inter-assay reproducibility, stability with delayed sample processing, and within-person reproducibility over time, but these antibody levels did not correlate with CAD risk or red meat intake. Antibodies against Neu5Gc alone or against individual Neu5Gc-bearing epitopes were also not associated with colorectal cancer (CRC) risk. However, a sialoglycan microarray study demonstrated positive association with CRC risk when the total antibody responses against all Neu5Gc-glycans were combined. Individuals in the top quartile of total anti-Neu5Gc IgG antibody concentrations had nearly three times the risk compared to those in the bottom quartile (Multivariate Odds Ratio comparing top to bottom quartile: 2.98, 95% CI: 0.80, 11.1; P for trend = 0.02). Conclusions: Further work harnessing the utility of these anti-Neu5Gc antibodies as biomarkers in red meat-associated diseases must consider diversity in individual antibody profiles against different Neu5Gc-bearing glycans. Traditional ELISA assays for antibodies directed against Neu5Gc alone, or against specific Neu5Gc-glycans may not be adequate to define risk associations. Our finding of a positive association of total anti-Neu5Gc antibodies with CRC risk also warrants confirmation in larger prospective studies.

Aberrant N-glycolylneuraminic acid in breast MCF-7 cancer cells and cancer stem cells.

Cell Surface-Specific N-glycan Profiling in Breast Cancer.

Comprehensive N-Glycome Profiling of Cells and Tissues for Breast Cancer Diagnosis.

Integrated Glycome Strategy for Characterization of Aberrant LacNAc Contained N-Glycans Associated with Gastric Carcinoma.

Polyclonal human antibodies against glycans bearing red meat-derived non-human sialic acid N-glycolylneuraminic acid are stable, reproducible, complex and vary between individuals: Total antibody levels are associated with colorectal cancer risk

Diversity in Specificity, Abundance, and Composition of Anti-Neu5gc Antibodies in Normal Humans: Potential Implications for Disease.

A novel analytical probe binding to a potential carcinogenic factor of N-glycolylneuraminic acid by SELEX.

Mass Spectrometry Analysis Reveals Aberrant N-glycans in Colorectal Cancer Tissues

Comparative site-specific N-glycoproteome analysis reveals aberrant N-glycosylation and gives insights into mannose-6-phosphate pathway in cancer

Characterization of an Aptamer Targeting Neu5Gc, as an Endogenous Pathogenic Factor Derived from Red Meat

Recognition of N-Glycoforms in Human Chorionic Gonadotropin by Monoclonal Antibodies and Their Interaction Motifs

Common Aberrations from the Normal Human Plasma N-glycan Profile.

Human Xeno-Autoantibodies Against A Non-Human Sialic Acid Serve As Novel Serum Biomarkers And Immunotherapeutics In Cancer

An N-glycome tissue atlas of 15 human normal and cancer tissue types determined by MALDI-imaging mass spectrometry

A Novel N-Tetrasaccharide In Patients With Congenital Disorders Of Glycosylation, Including Asparagine-Linked Glycosylation Protein 1, Phosphomannomutase 2, And Mannose Phosphate Lsomerase Deficiencies

Identification of Aberrantly Expressed Glycans in Gastric Cancer by Integrated Lectin Microarray and Mass Spectrometric Analyses.

Aberrant Glycosylation And Cancer Biomarker Discovery: A Promising And Thorny Journey

Analysis of mutation‐originated gain‐of‐glycosylation using mass spectrometry‐based N‐glycoproteomics

In-Depth Analysis of the N-Glycome of Colorectal Cancer Cell Lines

Lamprey Immunity Protein Enables Detection for Bladder Cancer Through Recognizing N-hydroxyacetylneuraminic Acid (Neu5gc)-Modified As a Diagnostic Marker and Exploration of Its Production Mechanism.

Accumulation of free complex-type N-glycans in MKN7 and MKN45 stomach cancer cells